R. Somaratne

发表

AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody in

R. Giugliano, M. Sabatine, N. Desai, 2014, Journal of the American College of Cardiology.

Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism

G. Watts, S. Wasserman, R. Scott, 2018, Arteriosclerosis, thrombosis, and vascular biology.

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role[S]

R. Giugliano, M. Sabatine, N. Seidah, 2016, Journal of Lipid Research.

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab

J. Minnier, S. Fazio, M. Shapiro, 2019, Journal of the American Heart Association.

Population pharmacokinetics and exposure–response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia

J. Gibbs, M. Emery, S. Wasserman, 2018, Journal of Pharmacokinetics and Pharmacodynamics.

AMG 145, A Monoclonal Antibody Against PCSK9, Significantly Reduces Lipoprotein (a) in Hypercholesterolemic Patients Receiving Statin Therapy: An Analysis From the LAPLACE-TIMI 57 Trial

R. Giugliano, M. Sabatine, N. Desai, 2013 .

Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.

M. Karsdal, J. Trotter, J. Drenth, 2019, Journal of hepatology.

Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolem

F. Raal, E. Stein, S. Wasserman, 2012 .

Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals

R. Giugliano, M. Sabatine, J. Gibbs, 2018, Journal of cardiovascular pharmacology and therapeutics.

Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting

J. Legg, C. Recknor, M. Geller, 2016, SpringerPlus.

Efficacy and Safety of the PCSK9 Inhibitor Evolocumab (AMG 145) in Patients with Type 2 Diabetes

Jennifer G. Robinson, J. Robinson, F. Raal, 2015 .

University of Birmingham Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis:

Harrison, M. Karsdal, J. Trotter, 2018 .

Cost‐Effectiveness of LDL‐C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States

G. Fonarow, B. van Hout, M. Lothgren, 2016, Clinical cardiology.

Effect of NGM 282 , a FGF 19 analogue , in Primary Sclerosing Cholangitis : a Multicentre , Randomized , Double-Blind , Placebo-Controlled Phase 2 Trial

M. Karsdal, J. Trotter, J. Drenth, 2018 .

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)

Marc P. Bonaca, B. Lewis, A. Keech, 2017, Circulation.

Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial

B. Lewis, A. Keech, R. Giugliano, 2017, JAMA cardiology.

Response by Watts et al to Letter Regarding Article, "Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism".

M. Sabatine, G. Watts, S. Wasserman, 2017, Circulation.

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study

R. Giugliano, M. Sabatine, N. Desai, 2012, The Lancet.

Design and Rationale of the LAPLACE‐TIMI 57 Trial: A Phase II, Double‐Blind, Placebo‐Controlled Study of the Efficacy and Tolerability of a Monoclonal Antibody Inhibitor of PCSK9 in Subjects With Hypercholesterolemia on Background Statin Therapy

R. Giugliano, M. Sabatine, N. Desai, 2012, Clinical cardiology.

Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study.

D. Gaudet, S. Gidding, F. Raal, 2018, Journal of clinical lipidology.

Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics

G. Watts, S. Marcovina, S. Wasserman, 2018, European heart journal.

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

A. Keech, R. Giugliano, M. Sabatine, 2017, The Lancet.

Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: Results of the randomized, controlled, open-label DE LAVAL study.

T. Sampietro, C. Kurtz, B. Hohenstein, 2019, Journal of clinical lipidology.

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

Jennifer G. Robinson, R. Giugliano, M. Sabatine, 2015, The New England journal of medicine.

Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia: The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterole

F. Raal, E. Stein, S. Wasserman, 2012, Circulation.

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

Lesley Burgess, Russell Scott, Rob Scott, 2015, The Lancet.

A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies

Jennifer G. Robinson, J. Robinson, E. Stroes, 2020, Cardiology and Therapy.

Rationale and design of a randomized study to assess the efficacy and safety of evolocumab in patients with diabetes and dyslipidemia: The BERSON clinical trial

J. Ge, Yundai Chen, A. Lorenzatti, 2018, Clinical cardiology.

Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism

G. Watts, S. Wasserman, R. Scott, 2017, Circulation.

Safety and effect of very low levels of low-density lipoprotein cholesterol on cardiovascular events.

J. Larosa, T. Pedersen, S. Wasserman, 2013, The American journal of cardiology.

Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease

Peter Lindgren, Yi Qian, Ben van Hout, 2017, JAMA cardiology.

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.

C. Ballantyne, S. Nissen, R. Rosenson, 2016, JAMA.

Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study

R. Rosenson, M. Daviglus, P. Reaven, 2019, Diabetologia.

Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency

Jeroen J. Bax, G. Hindricks, D. Atar, 2016, European journal of heart failure.

Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials.

R. Giugliano, M. Sabatine, R. Weiss, 2014, European heart journal.

Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study.

F. Prati, S. Windecker, S. Nissen, 2021, Cardiovascular diagnosis and therapy.

C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV

W. Koenig, C. Ballantyne, J. Kastelein, 2020, American journal of preventive cardiology.

Effect of Evolocumab on Coronary Plaque Composition.

W. Koenig, C. Ballantyne, J. Kastelein, 2018, Journal of the American College of Cardiology.

Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.

W. Koenig, C. Ballantyne, J. Kastelein, 2016, JAMA.

Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV).

W. Koenig, C. Ballantyne, J. Kastelein, 2016, American heart journal.

Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia: 52-Week Results From the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) Randomized Trial

R. Giugliano, M. Sabatine, F. Raal, 2014, Circulation.

Residual risk for coronary heart disease events and mortality despite intensive medical management after myocardial infarction.

M. Woodward, L. Colantonio, N. Limdi, 2020, Journal of clinical lipidology.

Determinants of Plaque Progression Despite Very Low Low-Density Lipoprotein–Cholesterol Levels With the PCSK9 Inhibitor, Evolocumab

J. Kastelein, S. Nissen, S. Nicholls, 2021, JACC: Cardiovascular Imaging.

Evolocumab: Considerations for the Management of Hyperlipidemia

B. Wiggins, Jeffrey Senfield, H. Kassahun, 2018, Current Atherosclerosis Reports.

Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor

J. Gibbs, M. Emery, M. Gibbs, 2018, Clinical Pharmacokinetics.

Long-term Low-Density Lipoprotein Cholesterol–Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study

R. Giugliano, M. Sabatine, F. Raal, 2017, JAMA cardiology.

Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.

Jennifer G. Robinson, Patric Nelson, S. Wasserman, 2014, JAMA.

Effect of Evolocumab on Lipoprotein Particles.

S. Martin, Steven R. Jones, N. Sattar, 2018, The American journal of cardiology.

Impact of Target‐Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

J. Gibbs, M. Emery, M. Gibbs, 2016, Journal of clinical pharmacology.

PCSK9 Variants, Low-Density Lipoprotein Cholesterol, and Neurocognitive Impairment: Reasons for Geographic and Racial Differences in Stroke Study (REGARDS)

V. Wadley, M. Farkouh, K. Monda, 2017, Circulation.

Rationale and Design of LAPLACE‐2: A Phase 3, Randomized, Double‐Blind, Placebo‐ and Ezetimibe‐Controlled Trial Evaluating the Efficacy and Safety of Evolocumab in Subjects With Hypercholesterolemia on Background Statin Therapy

Jennifer G. Robinson, Patric Nelson, S. Wasserman, 2014, Clinical cardiology.

Effect of evolocumab on cholesterol synthesis and absorption[S]

S. Wasserman, R. Scott, Ransi M. Somaratne, 2016, Journal of Lipid Research.

NGM282, an engineered analogue of FGF19, significantly improves markers of bile acid synthesis, hepatic injury and fibrosis in PSC patients: Results of a phase 2, multicenter, randomized, doubleblind, placebo-controlled trial

M. Karsdal, J. Trotter, J. Drenth, 2018 .

Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies

O. Descamps, N. Sattar, J. Genest, 2017, Circulation.

Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data.

Jennifer G. Robinson, N. Sattar, J. Robinson, 2016, The lancet. Diabetes & endocrinology.

LDL CHOLESTEROL REDUCTION IN ELDERLY PATIENTS WITH THE PCSK9 MONOCLONAL ANTIBODY EVOLOCUMAB (AMG 145): A POOLED ANALYSIS OF 1779 PATIENTS IN PHASE 2, 3 AND OPEN LABEL EXTENSION STUDIES

R. Rosenson, E. Stroes, N. Honarpour, 2015 .

Abstract 16865: Safety and Tolerability of Very Low LDL-C Levels in Patients Treated with 52 Weeks of Evolocumab (AMG 145)

R. Giugliano, E. Stroes, S. Wasserman, 2014 .

Safety of AMG 145, a fully human monoclonal antibody to PCSK9: Data from four phase 2 studies in 1314 patients

R. Giugliano, M. Sabatine, R. Weiss, 2013 .

Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety

J. Gibbs, M. Emery, S. Wasserman, 2019, Clinical pharmacology in drug development.

R. Giugliano, M. Sabatine, F. Raal, 2014, Circulation.

Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus.

N. Sattar, H. Soran, M. Cyrille, 2017, The American journal of cardiology.

Erratum to “Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency” [Eur J Heart Fail 2016;18:482‐489]

Jeroen J. Bax, G. Hindricks, D. Atar, 2016, European journal of heart failure.

R. Giugliano, M. Sabatine, R. Weiss, 2014, European heart journal.

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

Jennifer G. Robinson, R. Giugliano, M. Sabatine, 2015, The New England journal of medicine.

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

D. Gaudet, F. Raal, F. Civeira, 2015, The Lancet.

Lipoprotein(a), PCSK9 Inhibition and cardiovascular risk: Insights from the Fourier trial

R. Giugliano, M. Sabatine, M. O’Donoghue, 2018, Atherosclerosis.